Program
abelacimab
Also written as “Abelacimab”, “MAA868” and “MAA868 Cohort 1”.
In Novartis's pipeline, FXI/FXIa inhibitor
. Its studies are mostly in Atrial Fibrillation · Venous Thromboembolism, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Anthos Therapeutics | 52 open or running | phase 3since Nov 22, 2021 | Dec 23, 2019 | Dec 30, 2027phase 3 · NCT05712200 |
| Novartis | 31 open or running | phase 3since Jul 28, 2026 | Jan 3, 2018 | Dec 30, 2030phase 3 · NCT07739888 |
- Named in Novartis’s own pipeline as
MAA868 (abelacimab)
, phase 3, as of Nov 16, 2026 (source).
Also a collaborator on its studies: covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2018First studies: 2 phase 2 studiesNew to NovartisNovartis · NCT03393481, NCT03398434
- Dec 23, 2019Anthos Therapeutics's first study: phase 2 study in Atrial FibrillationNew to Anthos TherapeuticsAnthos Therapeutics · NCT04213807 · 28 enrolled · United States
- Feb 11, 2021Phase 2 study in Atrial FibrillationAnthos Therapeutics · NCT04755283 · 1,287 enrolled · United States, Canada, Czechia and more
- Nov 22, 20212 phase 3 studies in Venous ThromboembolismAnthos Therapeutics · NCT05171075, NCT05171049
- Jan 12, 2023Phase 3 study in Atrial FibrillationAnthos Therapeutics · NCT05712200 · 2,500 planned · United States, Argentina, Brazil and more
- Jul 28, 2026Phase 3 study in Atrial FibrillationPhase 3 reachedNovartis · NCT07739888 · 2,500 planned
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Atrial FibrillationAnthos Therapeutics · NCT05712200
- Dec 30, 2030Primary completion: phase 3 study in Atrial FibrillationNovartis · NCT07739888
TargetBeta
“FXI/FXIa inhibitor”the company's pipeline, read by Claude · source
“Coagulation factor XI inhibitor”ChEMBL 37, by rule
Other programs on F11
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07739888Atrial Fibrillation | 3 | Not yet recruiting | Novartis | Dec 30, 2030 | 2,500 |
| NCT05712200Atrial Fibrillation · United States, Argentina, Brazil and more | 3 | Recruiting | Anthos Therapeutics | Dec 30, 2027 | 2,500 |
| NCT05171075Venous Thromboembolism · United States, Australia, Austria and more | 3 | Terminated | Anthos Therapeutics | Apr 10, 2026 | 417 |
| NCT05171049Venous Thromboembolism · United States, Australia, Austria and more | 3 | Terminated | Anthos Therapeutics | Feb 4, 2026 | 1,150 |
| NCT04755283Atrial Fibrillation · United States, Canada, Czechia and more | 2 | Active, not recruiting | Anthos Therapeutics | Feb 15, 2024 | 1,287 |
| NCT04213807Atrial Fibrillation · United States | 2 | Completed | Anthos Therapeutics | Dec 29, 2020 | 28 |
| NCT03398434Atrial Fibrillation | 2 | Withdrawn | Novartis | Nov 28, 2019 | 0 |
| NCT03393481Venous Thromboembolism | 2 | Withdrawn | Novartis | Jan 8, 2020 | 0 |
How it is read
Names in the registry
- “Abelacimab”, 5 entries
- “MAA868”, 2 entries
- “MAA868 Cohort 1”, 1 entry
- “MAA868 Cohort 2”, 1 entry
- “MAA868 Cohort 3”, 1 entry
Conditions, from the studies’ own filings
- Atrial Fibrillation, 5 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.